FEMETRIC RESEARCH FEATURE
Women in Research
A source-linked view of female representation and sex-specific reporting where meaningful participant metadata is available. Missing metadata does not mean a peptide is unsafe or ineffective.
| PEPTIDE | STUDY | FEMALE PARTICIPANTS | % WOMEN | SEX-SPECIFIC RESULTS | VIEW |
|---|---|---|---|---|---|
| Retatrutide | Retatrutide for obesity — Phase 2Phase 2 · NCT04881760 | 163 | 48.2% | ReportedThe publication reported an exploratory difference in mean weight change by sex. It did not define female-specific study arms or a separate dose for women. | |
| PT-141 / Bremelanotide | Bremelanotide for hypoactive sexual desire disorder — RECONNECT phase 3 trialsPhase 3 · NCT02333071 · NCT02338960 | 1267 | 100.0% | ReportedThe two phase 3 trials enrolled premenopausal women and reported female sexual desire, related distress and adverse events; 1,247 were included in the safety population. | |
| Kisspeptin | Kisspeptin administration in women with hypoactive sexual desire disorderRandomized clinical trial · ISRCTN17271094 | 40 | 100.0% | ReportedThirty-two women completed both visits. The trial reported neuroimaging, psychometric and hormonal outcomes in women with HSDD. |
This index reports available metadata. It does not grade safety, effectiveness or study quality.